PLYMOUTH MEETING, Pa., Nov. 16, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's management team will participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY on Thursday, November 30, 2023, at 9:00 a.m. ET.
A webcast of the fireside chat will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/.
About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.
Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
This email address is being protected from spambots. You need JavaScript enabled to view it.
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$34.17 |
| Daily Change: | 0.04 0.12 |
| Daily Volume: | 376,045 |
| Market Cap: | US$1.950B |
April 08, 2025 February 19, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
